SPI

SPI handeln
18.826,51 PKT +347,91 PKT +1,88 %
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

WKN 998750

ISIN CH0009987501


Analysen zu SPI-Werten

Datum Rating Analyst
10.12.12 METALL ZUG hold Vontobel Research
10.12.12 Schweiter hold Vontobel Research
10.12.12 Basilea Pharmaceutica hold Vontobel Research
10.12.12 Basilea Pharmaceutica buy Sarasin Research
10.12.12 ARYZTA neutral Sarasin Research
07.12.12 Clariant hold Deutsche Bank AG
07.12.12 Givaudan sell Deutsche Bank AG
07.12.12 BELIMO hold Vontobel Research
07.12.12 Bucher Industries hold Vontobel Research
06.12.12 Nestlé hold Deutsche Bank AG
06.12.12 Orascom Development neutral Sarasin Research
05.12.12 Roche overweight J.P. Morgan Cazenove
05.12.12 UBS buy Deutsche Bank AG
05.12.12 Implenia buy Vontobel Research
05.12.12 Richemont hold Vontobel Research
04.12.12 OC Oerlikon buy UBS AG
04.12.12 Swiss Re buy Société Générale Group S.A. (SG)
04.12.12 Swiss Prime Site hold Vontobel Research
04.12.12 Sonova overweight Morgan Stanley
04.12.12 Richemont hold Renaissance Capital
04.12.12 Julius Bär reduce Vontobel Research
04.12.12 OC Oerlikon buy Vontobel Research
03.12.12 ARYZTA hold Vontobel Research
03.12.12 Nestlé hold Vontobel Research
03.12.12 Kühne + Nagel International hold Vontobel Research
03.12.12 Galenica reduce Vontobel Research
03.12.12 Zurich Insurance buy Nomura
03.12.12 ARYZTA neutral Sarasin Research
03.12.12 Nestlé overweight Morgan Stanley
03.12.12 Swatch (I) buy Goldman Sachs Group Inc.
03.12.12 Clariant underperform Credit Suisse Group
30.11.12 ABB (Asea Brown Boveri) neutral HSBC
30.11.12 Zurich Insurance neutral J.P. Morgan Cazenove
30.11.12 UBS outperform Exane-BNP Paribas SA
30.11.12 ARYZTA hold Société Générale Group S.A. (SG)
30.11.12 Roche buy Sarasin Research
30.11.12 Holcim hold Société Générale Group S.A. (SG)
30.11.12 Holcim overweight Morgan Stanley
30.11.12 Holcim equal-weight Morgan Stanley
30.11.12 Novartis outperform Sanford C. Bernstein and Co., Inc.